Life Sciences Archive » December, 2014

Life Sciences - December, 2014

247 articles

• Covidien, Medtronic Settle Investor Suit Over $42.9B Merger
• Actavis Jumped Gun On Allergan Eye Drug ANDA, Judge Says
• Deals Rumor Mill: Stryker, HeidelbergCement, BeijingWest
• FDA Plans To Alter Lifetime Ban On Gay Male Blood Donation
• Fed. Circ. Ruling Moots Derivative Suit, Zimmer Tells Chancery
• Court OKs Medtronic Payments For Board's Inversion Taxes
• Ex-NFLer Wants SEC Claims Sacked From Pump-Dump Claim
• Plaintiff Asks Fla. Judge To Deny Stiefel's Recusal Request
• Judge Pauses NY AG's Actavis Injunction Amid Appeal
• J&J Penalties Help US Atty's Office Pull In $2.3B In FY 2014
• PTAB Nixes 'Recycled' Bid For AIA Review Of Suboxone Patent
• Oscar Winner Nabs $1M Deal Win After Sensa Attys Quit
• Ex-Orioles Player Says Newman Strikes Out Insider Charges
• 3 Life Sciences Cos. Tune IPO Plans Ahead Of New Year
• 5 NJ Accutane Suits Survive Timeliness Challenge
• Stryker Can't Shake Suit Over Bone Medical Devices
• FDA Hints At Legal Action Against Powdered Caffeine Sales
• ITC Says Indian IP, Investment Policies Stifling US Biz
• DOJ Intervenes In FCA Suits Accusing Omnicare Of Kickbacks
• Nixon Peabody, Mintz Levin Blitz Biotech's Legal Mal Suit
• Paris Appeals Court Backs €40.6M Antitrust Fine For Sanofi
• FDA Digs In Heels On Orphan Drug Exclusivity
• SEC Launches Insider-Trading Suit Over $3.3B Abbott Deal
• FTC Report Finds Decline In Potential Pay-For-Delay Deals
• SEC Fines Calif.-Based Atty For Trading On Client's Intel
• Nexium Buyers Call Appeal Dismissal Bid 'Gamesmanship'
• FTC Approves $5.4B Eli Lilly-Novartis Deal With Divestiture
• JPML Asked To Combine Suits Over Daiichi's Benicar In Ohio
• Amazon Fights Class Action On Dangerous Diet Drug Sales
• PTAB Nixes Warsaw Spine Implant Patent In AIA Review
• The Biggest M&A Moments Of 2014: Second Half
• Judge Denies Class Cert. In Cymbalta Withdrawal Risks Suit
• J&J Could Pay Out Up To $700M In Deal To Boost Cancer Biz
• UConn Health Center Must Name Researchers Sought By PETA
• Product Liability In 2014: What Did And Didn't Happen?
• Judge Won't Alter Atty's 17-Year Stock Scheme Sentence
• The State Of Technology-Assisted Review In 2014
• Law360 Names Law Firms Of The Year
• Law360 Names Practice Groups Of The Year
• Ch. 11 Case For Skin Treatment Co. Thrown Out
• Growth Hormone Biotech Seeks $86M IPO Amid Strong Market
• Mylan Can Ask Fed. Circ. To Weigh Hatch-Waxman Jurisdiction
• K&L Gates Lands Deals Ace From LipoScience In NC
• Becton Didn't Hold Monopoly Power, Judge Rules
• EU Approves €385M IMS-Cegedim Deal Pending Fixes
• SG Says High Court Shouldn't Hear Teva Drug Label Case
• Reckitt Asks Judge To Again Consider Axing Suboxone Suit
• 5 IPOs Reap $1B In Last Full Week Of Record-Busting 2014
• Teva, Pliva Ask High Court To Weigh Pa. Reglan Preemption
• Player Recruiter Pleads Guilty In Biogenesis Doping Case
• Fed. Circ. Slashes Stryker's $210M Patent Damages Award
• Good Luck Guessing With The Gov't On Gainsharing
• Feds Won't Interfere With States' Medical Marijuana Laws
• Onyx Traders Say Newman Undermines SEC Insider Case
• AllPure Says Fed. Circ. Needn't Revisit Device Patent Ruling
• The Biggest M&A Moments Of 2014: First Half
• 2nd Cancer Biotech Of The Week Soars In Market Debut
• Pay-For-Delay In 2014: Courts Fill In The Actavis Gaps
• Fed. Circ. Got Original-Patent Rule Wrong, Antares Says
• Ex-Retrophin CEO Gave Away Stock, Investor Suit Says
• EU's Top Court Opens Door to Some Stem Cell Patents
• Merck Will Drop Up To $375M On Cancer Treatment Co.
• Holland & Knight Adds Fla. Health Care Policy Coordinator
• Drug Supplier In MLB Doping Scandal Pleads Guilty
• FDA Raps Sunovion Pharma For Bogus Benefit Claims
• Cancer Biotech Bellicum Soars After $140M IPO Trumps Range
• Mylan Loses 4th Challenge Of Gilead Viread Patent
• USPTO Is Rejecting Potentially Life-Saving Inventions
• Dendreon Gets Nod For Bondholder Support Deals
• Many Biotech Patents At Risk After Fed. Circ. Myriad Ruling
• Fed. Circ. Strikes Down More Myriad Cancer Test Patents
• Watson Beats Auxilium's Testim Patent Suit In Court Trial
• 8th Circ. Affirms Bayer's FCA Loss But Trims Damages
• Kline And Specter Take On Philly's Plaintiff-Friendly Rep
• Allergan Investors Accuse Valeant, Pershing Of Takeover Plot
• Advent, Avista Drop $1.5B Drug Co. Buy Amid FDA Scrutiny
• PTAB Won't Review Orthophoenix Bone Tool Patents
• Philips Puts Down $1.2B For Medical Device Manufacturer
• What Happens When Legal Aid Cuts Stimulate Pro Bono?
• FDA To Review Apotex Biosimilar Of Amgen Blockbuster Drug
• Option Deals For Biotech: Ensuring They Are Enforceable
• NECC Prez Charged With Murder Over Meningitis Outbreak
• Another Big Year For ITC: Top 12 Section 337 Highlights
• Full Fed. Circ. Won't Review Nixing Of Apotex Patent
• Order Impeded Arbitration Appeal In Avandia Fee Fight: Court
• CMS Clouds Stance On Open Payments Exemption
• New FDA Rule Will Enforce Electronic Drug Labeling
• Cancer Biotech Juno Eyes $204M IPO With Increased Terms
• Ex-Employee Accuses Abbott Of Retaliation In FCA Suit
• 8th Circ. Asked To Nix Attys' Support Of Jones Day Sanctions
• 4th Circ. Revives Challenge To Generic Celebrex Exclusivity
• FTC Says Reckitt Still Holding Back Suboxone Docs
• Biotech Acquisition Co. Prices $40M IPO
• Top FDA Aide Joins Boies Schiller's Gov't Response Team
• Drugmakers Can't DQ Cohen Milstein In Chicago Opioid Suit
• 7th Circ. Explains Role Of Objectors In Class Settlement
• A Look At 2014 Fed. Circ. Cases Impacting AIA Proceedings
• Top 10 Trade Secrets Developments Of 2014: Part 1
• SEC To Drop Insider Trading Case Over Herbalife Stock
• Actavis Can't Delay Injunction In 'Product Hopping' Case
• Chancery Halts Zimmer Investor Claims During Patent Appeal
• New USPTO Guidance Has Fewer Limits On Patent Eligibility
• Skadden Atty Testifies On Failed $21B J&J-Guidant Merger
• FTC Urges Court Not To Nix AbbVie Pay-For-Delay Suit
• High Court Clears Air On Class Action Removal Disputes
• Judge Fines Viora for Motion 'Escapade' In Syneron IP Feud
• Purdue's 'New' Oxycodone Pills Are Copycats, Acura Says
• Fed. Circ. Gives Promega 2nd Shot In $52M LifeTech IP Fight
• Forest Gets Some Relief In Lexapro Marketing MDL
• The 5 Biggest M&A Failures Of 2014
• Inside New Fed. Circ. Practice Notes For Expedited Appeals
• High Court Ruling Sets Low Bar For Class Action Removal
• FTC Centennial: How Health Care Antitrust Has Evolved
• 3 Questions To Ask Yourself Before Hiring Appellate Counsel
• NJ Bill Would Apply False Claims Act Provisions Retroactively
• Xarelto Safety Suits Sent To Louisiana By MDL Panel
• NJ State Court Tosses Hundreds Of Accutane Suits
• JPML Sends Opana Pay-For-Delay Suits To Illinois
• JPML Again Won't Combine USPlabs Diet Supplement Suits
• Civitas Therapeutics Drops IPO Plan In Wake Of Acorda Deal
• Amid Push For Growth, Danone Says $3.7B Unit Isn't For Sale
• Taxation With Representation: Hughes Hubbard, Hogan, Ropes
• 6 Questions To Ask Before An Internal Investigation
• Judge In Actavis Antitrust Suit Keeps Namenda On Market
• Dendreon Bondholder Support Deal Comes Under Fire
• FDA Warns Pfizer Geodon Drug Could Cause Deadly Rash
• AstraZeneca Drops 1st Circ. Row Over Nexium Class Cert.
• Boiron Colluded On Deal Over Flu Remedies, 9th Circ. Told
• Pa. Transit Agency Slaps Gilead With Price-Gouging Suit
• CORRECTED: PTAB Rejects Mylan's Challenge To Gilead's Viread Patent
• What Lawyer-Novelists Learned From Being Lawyers
• Patent Suit Implicating Pitt In Stealing Vaccine Tossed
• BioMed Nets $322.5M In Sale Of GSK Unit's Facility
• Fed. Circ. Won't Disturb Block On Sandoz Combigan Generic
• 11th Circ. Confirms Experts Must Prove Causation
• CMS Databases Increase Qui Tam Risk For Health Providers
• CSPI Urges FDA To Ban Powdered Caffeine Sales
• JPML Refuses To Consolidate Cymbalta Cases
• Siemens' $3.6M Settlement With HearUSA Stockholders OK'd
• Reckitt Accuses FTC Of Skirting Court's Instructions
• Actavis, NY AG Differ On Suboxone Ruling On Antitrust Suit
• Deals Rumor Mill: Danone Groupe, Vestas, Fosun International
• Life Sciences MVP: Irell & Manella's David Gindler
• 2014 Year In Review Of US Biosimilar Activity
• Abbott Asks 7th Circ. To Affirm Toss Of Off-Label Use Suit
• PTAB Backs 3 Oracea Patents In 1st-Ever Pharma AIA Ruling
• CORRECTED: Genentech Sinks Bid For AIA Review Of Cancer Drug Patent
• Fed. Circ. Hands USPTO Win In Cancer Patent Disclaimer Row
• NuVasive Again Dodges Medicare Probe Securities Class Suit
• Bidder-Activist Collaboration Will Continue To Evolve
• Lupin Fights EU's 'Wholly Novel' Pay-For-Delay Fine
• Millennium Beats IPXpharma's Cancer Drug Patent Suit
• Drunken Drivers Can't Bring BAC Tester Claims, 3rd Circ. Says
• Deals Rumor Mill: JCDecaux, Valeant, AAR Corp.
• Market Rumors: Valeant Pharmaceuticals, Santander, Ardagh
• Life Sciences MVP: Morgan Lewis' Randy Sunberg
• Juno Nears Biggest Biotech Mark With $153M IPO Plan
• CR Bard Fights Consolidation Of Suits In Pelvic Mesh MDL
• 3rd Circ. Affirms Revival Of Genaera Investor Suit
• Ebola Vaccine Makers Get Liability Immunity From HHS
• Becton Seeks Stay Of Injunction In $340M Antitrust Suit
• Gov't Paying Close Attention To Patient Assistance Programs
• Hospira Gets 4 Of 5 Cubicin Patents Nixed
• Nexium Verdict No Final Word On Pay-For-Delay
• 2014 FDA Year In Review: Food Edition
• Indian Officials Conditionally Approve $3.2B Ranbaxy Sale
• Plaintiffs' Expert In CR Bard Pelvic Mesh MDL Disqualified
• OtisMed, Ex-CEO Cop To Distributing Device After FDA Denial
• High Court Won't Review Glenmark's $16M Tarka Patent Loss
• Zoll Seeks High Court Review Of IPR Rejection Appeal Rules
• No New Trial For Two Convicted ArthroCare Executives
• Stiefel Labs Pushes For Judge's Recusal In ERISA Suit
• High Court Won't Hear Braintree's Claim Construction Appeal
• Life Sciences MVP: Fried Frank's David Shine
• Merck Keeps Pharma M&A Flowing With $9.5B Cubist Pickup
• Bayer's Flintstones Gummies Don't Boost Brains, Suit Says
• Gilead Seeks High Court Review Of Double-Patenting Row
• Fed. Circ. Says Sandoz Attack On Amgen Patents Is Premature
• Atty In NFLer Stock Scheme Sentenced To 17 Years
• Lone Biotech Braves IPO As Tech Braces For Year-End Rush
• Deals Rumor Mill: Merro, TDC, Alex & Ani
• Taxation With Representation: Skadden, Cravath, Latham
• Supplement Seller's Religion Claims Against Texas AG Tossed
• Who Is Responsible For Clinical Trial Informed Consent?
• Hagens Berman May Face Sanctions In Pa. Thalidomide Cases
• Life Sciences MVP: White & Case's Robert Milne
• Jury Hands AstraZeneca Win In Nexium Pay-For-Delay Case
• Compound Pharm Pleads Guilty To Shipping Tainted Steroids
• Minority Powerbrokers Q&A: Sanford Heisler's Felicia Medina
• En Banc 9th Circ. To Weigh FCA's Public Knowledge Bar
• Sens. Look To Block FDA Oversight Of Medical Apps
• Sandoz Urges Fed Circ. To Revive Combigan Generic Bid
• Subject Of Chancery Arrest Warrant Claims Discrimination
• FDA Tries To Tame Antitrust Wars Over Dangerous-Drug Sales
• Gov't Rejects ArthroCare Execs' 6th Amendment Claims
• Reckitt Can't Escape Antitrust Case Over 'Product-Hopping'
• Deals Rumor Mill: Oi, Fortum, Arbor Pharmaceuticals
• Fed. Circ. Reverses $176M Award In J&J Patent Row
• Chinese Regulators OK $43B Medtronic-Covidien Inversion
• BTG To Pay Up To $475M For Emphysema Treatment Maker
• Life Sciences MVP: Paul Hastings' Joe O'Malley
• NECC Ch. 11 Plan Sets Aside $135M For Outbreak Victims
• Post-Nautilus, Post-Interval: Indefiniteness In November
• Sanofi Paid $34M In Drug Kickbacks, Whistleblower Claims
• Nexium Buyers End Trial Saying AstraZeneca Paid Off Rivals
• Bausch & Lomb Violated ERISA With Execs' Payout: 2nd Circ.
• Zimmer Prevails In 1st Durom Hip Implant Trial
• Pa. High Court Won't Hear Asbestos Suits Transfer Appeal
• Dental Implant Co. Ordered To Pay $122K For Destroying Docs
• Life Sciences MVP: Kirkland & Ellis' Jay Lefkowitz
• NuVasive Ducks Atty Fees After Neurovision's $30M Jury Win
• Histogenics Misses Mark To Raise $65M In IPO
• Fed. Circ. Revives Par Pharma's Appetite Drug Patent
• Market Rumors: CGN, 1MDB, Phytotech
• FDA Overhauls Drug Risk Disclosures For Pregnant Women
• Texas Court Revives Emotional Distress Claim Against Firm
• Vitamin C Cos. Cite Motorola In 2nd Circ. Antitrust Appeal
• And Now A Word From The Panel: End Of An Era
• Ex-ArthroCare CFO Also Seeks Retrial In $756M Fraud Case
• Quarles & Brady Lands IP Partner From Kelley Drye
• Secret PTO Program Subjects Apps To Heightened Scrutiny
• No Proof Of Big Payment, AstraZeneca Says At Nexium Trial
• Market Rumors: Uber, Vale, Medtronic
• Jones Day Reps Riverside In Second Exit In Two Days
• Sigmapharm Asks Fed. Circ. For Legal Fees In Gilead IP Row
• Sophisticated Deals Attys Aren't Immune To Hackers' Guile
• 8th Circ. Spares Pliva In Generic Failure-To-Update Suit
• Omnicare, Dr. Reddy's Beat Medicare Insurer's FCA Suit
• Otsuka To Bolster Drug Pipeline With $3.5B Avanir Buy
• Stericycle Will Move Incinerator, Pay $1.2M In Utah DEQ Deal
• Mylan Challenges $4.4M IRS Deficiency Over Forest Lab Deal
• Life Sciences MVP: Sullivan & Cromwell's Matt Hurd
• Caution: Flaws Of The Attorney-To-Secretary Ratio
• So You Want To Do Business With The Saudi Government
• Medtronic Offers $17B In Bonds To Finance Covidien Deal
• Premature IP Action Over Kennedy Trust's Remicade Tossed
• FDA Boosts Warning On Biogen's MS Drug After Rare Death
• High Court Rejects Takeda Petition Over Prevacid Generic
• Ex-Va. Gov. McDonnell, Wife Lose Bid For New Trial
• Apotex Asks Fed. Circ. To Toss $76M AstraZeneca IP Win
• Companies Can't Turn Blind Eye To Whistleblowers
• 1st Circ. Nixes $30M Baxter FCA Suit Under First-To-File
• No Deal Was Reached In Mylan IP Row, Endo Tells Fed. Circ.
• GCs Name Most Arrogant Law Firms
• GCs Add 35 Firms To List Of Most Arrogant
• High Court Won't Hear Stryker's Hospital Bed Patent Case
• High Court Leaves Merck Licensing Row In Arbitration